{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranitidine+HCL&page=2",
    "query": {
      "intervention": "Ranitidine HCL",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranitidine+HCL&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T20:24:53.441Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00527878",
      "title": "Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "JOB's Syndrome",
        "Hyper-IgE Recurrent Infection Syndrome",
        "Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "Ranitidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-09",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2013-02-04",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527878"
    },
    {
      "nct_id": "NCT02999633",
      "title": "Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-cell Type Acute Leukemia-Precursor",
        "T-lymphoblastic Lymphoma/Leukaemia"
      ],
      "interventions": [
        {
          "name": "Isatuximab SAR650984",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "ranitidine",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-03-08",
      "completion_date": "2017-11-14",
      "has_results": true,
      "last_update_posted_date": "2022-03-21",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Hackensack, New Jersey • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02999633"
    },
    {
      "nct_id": "NCT02966665",
      "title": ": Vascular Function in Health and Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Pulmonary Artery Hypertension",
        "Heart Failure",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Maximum Exercise Tests",
          "type": "OTHER"
        },
        {
          "name": "BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate",
          "type": "DRUG"
        },
        {
          "name": "BQ-123",
          "type": "DRUG"
        },
        {
          "name": "Fexofenadine, Ranitidine",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin-II, Valsartan",
          "type": "OTHER"
        },
        {
          "name": "Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine",
          "type": "DRUG"
        },
        {
          "name": "BQ-123, MitoQ, BH4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "D. Walter Wray",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2008-09",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02966665"
    },
    {
      "nct_id": "NCT04397445",
      "title": "Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ranitidine Adverse Reaction",
        "Pharmacokinetics",
        "Food-drug Interaction"
      ],
      "interventions": [
        {
          "name": "Ranitidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low nitrite/NDMA meals",
          "type": "OTHER"
        },
        {
          "name": "High nitrite/NDMA meals",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Food and Drug Administration (FDA)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-06-08",
      "completion_date": "2020-07-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-09",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04397445"
    },
    {
      "nct_id": "NCT02655458",
      "title": "Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "autologous PBMC reconstitution",
          "type": "OTHER"
        },
        {
          "name": "ASCT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hearn Jay Cho",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-01",
      "completion_date": "2017-07-13",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02655458"
    },
    {
      "nct_id": "NCT01682408",
      "title": "Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)",
          "type": "DRUG"
        },
        {
          "name": "Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed",
          "type": "DRUG"
        },
        {
          "name": "Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)",
          "type": "DRUG"
        },
        {
          "name": "Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)",
          "type": "DRUG"
        },
        {
          "name": "Ranitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-09",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2012-12-28",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682408"
    },
    {
      "nct_id": "NCT01248962",
      "title": "Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 146,
      "start_date": "2010-11",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01248962"
    },
    {
      "nct_id": "NCT01649947",
      "title": "Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Advanced Non-small Cell Lung Cancer",
        "Recurrent Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-12-23",
      "completion_date": "2015-06-30",
      "has_results": true,
      "last_update_posted_date": "2022-11-21",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 2,
      "location_summary": "Hamilton, New Jersey • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01649947"
    },
    {
      "nct_id": "NCT01411410",
      "title": "Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib (BAY80-6946)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2011-08-24",
      "completion_date": "2015-06-29",
      "has_results": false,
      "last_update_posted_date": "2017-10-11",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01411410"
    },
    {
      "nct_id": "NCT03541408",
      "title": "Preventative Delirium Protocol in Elderly Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Delirium"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "OTHER"
        },
        {
          "name": "Preventative Delirium Protocol",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "65 Years to 89 Years"
      },
      "enrollment_count": 263,
      "start_date": "2016-05-01",
      "completion_date": "2021-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-09-25T20:24:53.441Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03541408"
    }
  ]
}